← All trials
NCT06287528
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 23, 2024
- Primary completion
- Feb 23, 2028
- Completion date
- Feb 23, 2028
- First posted
- Mar 1, 2024
- Last posted
- Jul 16, 2024
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Memorial Sloan-Kettering Cancer CenterOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.